Skip to content
2000
Volume 6, Issue 4
  • ISSN: 2666-7967
  • E-ISSN: 2666-7975

Abstract

Background

Nowadays, one of the best ways to manage COVID-19 is to understand the characteristics of patients and the risk factors associated with the disease.

Objective

This study aimed to investigate and compare the characteristics, symptoms, and prognosis of inpatients and outpatients with COVID-19 in Poledokhtar city.

Methods

In this descriptive-analytical study, 288 patients who tested positive for COVID-19 through PCR tests at COVID-19 screening centers and Imam Khomeini Hospital in Poledakhtar city were selected using the census method. They were divided into inpatient and outpatient groups. Data from patient files were collected and analyzed using SPSS version 25 software.

Results

The study revealed significant differences in age, comorbidities, prior infection, and aspirin use between the inpatient and outpatient groups. Cough was the most common symptom among all patients, with weakness and fatigue being more common in inpatients and cough being more prevalent in outpatients. The overall mortality rate was 5.2%, with inpatients having a worse prognosis compared to outpatients.

Conclusion

In the present study, inpatients were found to be older, have more underlying health conditions, fewer prior infections, and experience a poorer prognosis than outpatients. Given that patients may be asymptomatic or have mild symptoms upon admission, evaluating other patient factors is crucial in assessing disease severity.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/covid/10.2174/0126667975301350240627094313
2024-07-05
2025-10-03

  • From This Site

    /content/journals/covid/10.2174/0126667975301350240627094313
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. RothanH.A. ByrareddyS.N. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak.J. Autoimmun.202010910243310.1016/j.jaut.2020.102433 32113704
     [Google Scholar]
  2. PeirisJ.S.M. YuenK.Y. OsterhausA.D.M.E. StöhrK. The severe acute respiratory syndrome.N. Engl. J. Med.2003349252431244110.1056/NEJMra032498 14681510
     [Google Scholar]
  3. de GrootR.J. BakerS.C. BaricR.S. Middle East respiratory syndrome coronavirus (MERS-CoV): Announcement of the Coronavirus Study Group.J. Virol.201387147790779210.1128/JVI.01244‑13 23678167
     [Google Scholar]
  4. WuZ. McGooganJ.M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the chinese center for disease control and prevention.JAMA2020323131239124210.1001/jama.2020.2648
     [Google Scholar]
  5. MuccariR ChowD MurphyJ. Coronavirus timeline: tracking the critical moments of COVID-19. NBCNews.Available from: https://www.nbcnews.com/health/health-news/coronavirus-timeline-tracking-critical-moments-covid-19-n1154341 [updated 2020 March; cited 2020 September]
  6. SohrabiC. AlsafiZ. O’NeillN. World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19).Int. J. Surg.202076717610.1016/j.ijsu.2020.02.034 32112977
     [Google Scholar]
  7. WorldometerCOVID-19 coronavirus pandemic.Available from: https://www.worldometers.info/coronavirus/ [Cited: 29th December 2023].
  8. World Health OrganizationReport of the WHO-China Joint Mission on Coronavirus Disease.2019Available from: https://www.who.int/publications/i/item/report-of-the-who-china-joint-mission-on-coronavirus-disease-2019-(covid-19) [Cited: 16- 24th February 2020].
     [Google Scholar]
  9. MachhiJ. HerskovitzJ. SenanA.M. The natural history, pathobiology, and clinical manifestations of SARS-CoV-2 infections.J. Neuroimmune Pharmacol.202015335938610.1007/s11481‑020‑09944‑5 32696264
     [Google Scholar]
  10. Hernández RodríguezJ. Aspectos clínicos relacionados con el Síndrome Respiratorio Agudo Severo (SARS-CoV-2).Rev haban cienc méd2020191e3279
     [Google Scholar]
  11. ParasherA. COVID-19: Current understanding of its pathophysiology, clinical presentation and treatment.Postgrad. Med. J.202197114731232010.1136/postgradmedj‑2020‑138577 32978337
     [Google Scholar]
  12. DaiY. HuG. XiongH. QiuH. YuanX. Psychological impact of the coronavirus disease 2019 (COVID-19) outbreak on healthcare workers in China.medRxiv202010.1101/2020.03.03.20030874
     [Google Scholar]
  13. McCulloughP.A. AlexanderP.E. ArmstrongR. Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19).Rev. Cardiovasc. Med.202021451753010.31083/j.rcm.2020.04.264 33387997
     [Google Scholar]
  14. ProcterB.C. RossC. PickardV. SmithE. HansonC. McCulloughP.A. Clinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infection.Rev. Cardiovasc. Med.202021461161410.31083/j.rcm.2020.04.260 33388006
     [Google Scholar]
  15. AlexanderP.E. ArmstrongR. FareedG. Early multidrug treatment of SARS-CoV-2 infection (COVID-19) and reduced mortality among nursing home (or outpatient/ambulatory) residents.Med. Hypotheses202115311062210.1016/j.mehy.2021.110622 34130113
     [Google Scholar]
  16. McCulloughP.A. KellyR.J. RuoccoG. Pathophysiological basis and rationale for early outpatient treatment of SARS-CoV-2 (COVID-19) infection.Am. J. Med.20211341162210.1016/j.amjmed.2020.07.003 32771461
     [Google Scholar]
  17. BelaynehA. Off-label use of chloroquine and hydroxychloroquine for COVID-19 treatment in africa against who recommendation.Res. Rep. Trop. Med.202011617210.2147/RRTM.S269936 32982538
     [Google Scholar]
  18. MegaE.R. Latin America’s embrace of an unproven COVID treatment is hindering drug trials.Nature2020586783048148210.1038/d41586‑020‑02958‑2 33077974
     [Google Scholar]
  19. FanL. JiangS. YangX. WangZ. YangC. COVID-19 drug treatment in China.Curr. Pharmacol. Rep.20206414615410.1007/s40495‑020‑00218‑5 32837851
     [Google Scholar]
  20. HongK.S. JangJ.G. HurJ. Early hydroxychloroquine administration for rapid severe acute respiratory syndrome coronavirus 2 eradication.Infect. Chemother.202052339640210.3947/ic.2020.52.3.396 32757497
     [Google Scholar]
  21. GérardA. RomaniS. FresseA. “Off-label” use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers.Therapie202075437137910.1016/j.therap.2020.05.002 32418730
     [Google Scholar]
  22. VoraA. AroraV.K. BeheraD. TripathyS.K. White paper on Ivermectin as a potential therapy for COVID-19.Indian J. Tuberc.202067344845110.1016/j.ijtb.2020.07.031 32825892
     [Google Scholar]
  23. MorishitaM. HojoM. Treatment options for patients with severe COVID-19.Glob. Health Med.2023529910510.35772/ghm.2023.01024 37128231
     [Google Scholar]
  24. WangX. ZhangX. HeJ. Challenges to the system of reserve medical supplies for public health emergencies: Reflections on the outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic in China.Biosci. Trends20201413810.5582/bst.2020.01043 32062645
     [Google Scholar]
  25. EmanuelE.J. PersadG. UpshurR. Fair allocation of scarce medical resources in the time of COVID-19.N. Engl. J. Med.2020382212049205510.1056/NEJMsb2005114 32202722
     [Google Scholar]
  26. Centers for Disease Control and Prevention Coronavirus Disease 2019 (COVID-19)2019Available from: https://covid.cdc.gov/covid-data-tracker/#cases_casesper100klast7days [Cited: 25th January 2021].
  27. YanX. HanX. PengD. Clinical characteristics and prognosis of 218 patients with COVID-19: A retrospective study based on clinical classification.Front. Med.2020748510.3389/fmed.2020.00485 32850925
     [Google Scholar]
  28. ZhouF. YuT. DuR. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study.Lancet2020395102291054106210.1016/S0140‑6736(20)30566‑3 32171076
     [Google Scholar]
  29. LiX. XuS. YuM. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan.J. Allergy Clin. Immunol.2020146111011810.1016/j.jaci.2020.04.006 32294485
     [Google Scholar]
  30. PetrilliC.M. JonesS.A. YangJ. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: Prospective cohort study.BMJ2020369m196610.1136/bmj.m1966 32444366
     [Google Scholar]
  31. StefanN. BirkenfeldA.L. SchulzeM.B. LudwigD.S. Obesity and impaired metabolic health in patients with COVID-19.Nat. Rev. Endocrinol.202016734134210.1038/s41574‑020‑0364‑6 32327737
     [Google Scholar]
  32. KassD.A. DuggalP. CingolaniO. Obesity could shift severe COVID-19 disease to younger ages.Lancet2020395102361544154510.1016/S0140‑6736(20)31024‑2 32380044
     [Google Scholar]
  33. ZhangH. PenningerJ.M. LiY. ZhongN. SlutskyA.S. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target.Intensive Care Med.202046458659010.1007/s00134‑020‑05985‑9 32125455
     [Google Scholar]
  34. GuanW. NiZ. HuY. Clinical characteristics of coronavirus disease 2019 in China.N. Engl. J. Med.2020382181708172010.1056/NEJMoa2002032 32109013
     [Google Scholar]
  35. BrojakowskaA. NarulaJ. ShimonyR. BanderJ. Clinical implications of SARS-Cov2 interaction with renin angiotensin system.J. Am. Coll. Cardiol.202075243085309510.1016/j.jacc.2020.04.028 32305401
     [Google Scholar]
  36. WilliamsB. ManciaG. SpieringW. 2018 ESC/ESH Guidelines for the management of arterial hypertension.Eur. Heart J.201839333021310410.1093/eurheartj/ehy339 30165516
     [Google Scholar]
  37. SarduC. MaggiP. MessinaV. Could anti‐hypertensive drug therapy affect the clinical prognosis of hypertensive patients with COVID‐19 infection? data from centers of southern Italy.J. Am. Heart Assoc.2020917e01694810.1161/JAHA.120.016948 32633594
     [Google Scholar]
  38. SarduC. MarfellaR. MaggiP. Implications of AB0 blood group in hypertensive patients with COVID-19.BMC Cardiovasc. Disord.202020137310.1186/s12872‑020‑01658‑z 32799852
     [Google Scholar]
  39. WangW. XuY. GaoR. Detection of SARS-CoV-2 in different types of clinical specimens.JAMA2020323181843184410.1001/jama.2020.3786 32159775
     [Google Scholar]
  40. YoungB.E. OngS.W.X. KalimuddinS. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore.JAMA2020323151488149410.1001/jama.2020.3204 32125362
     [Google Scholar]
  41. SarduC. GargiuloG. EspositoG. PaolissoG. MarfellaR. Impact of diabetes mellitus on clinical outcomes in patients affected by Covid-19.Cardiovasc. Diabetol.20201917610.1186/s12933‑020‑01047‑y 32527257
     [Google Scholar]
  42. SarduC. D’OnofrioN. BalestrieriM.L. Outcomes in patients with hyperglycemia affected by COVID-19: Can we do more on glycemic control?Diabetes Care20204371408141510.2337/dc20‑0723 32430456
     [Google Scholar]
  43. MarfellaR. PaolissoP. SarduC. Negative impact of hyperglycaemia on tocilizumab therapy in Covid-19 patients.Diabetes Metab.202046540340510.1016/j.diabet.2020.05.005 32447102
     [Google Scholar]
  44. LiuB. LiM. ZhouZ. GuanX. XiangY. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?J. Autoimmun.202011110245210.1016/j.jaut.2020.102452 32291137
     [Google Scholar]
  45. ZhangC. WuZ. LiJ.W. ZhaoH. WangG.Q. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality.Int. J. Antimicrob. Agents202055510595410.1016/j.ijantimicag.2020.105954 32234467
     [Google Scholar]
  46. Jung J, Sung H, Kim SH. COVID-19 breakthrough infections in vaccinated health care workers.N. Engl. J. Med.2021385171629163110.1056/NEJMc2113497 34587378
     [Google Scholar]
  47. GrasselliG. ZangrilloA. ZanellaA. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy.JAMA2020323161574158110.1001/jama.2020.5394 32250385
     [Google Scholar]
  48. BhatrajuP.K. GhassemiehB.J. NicholsM. COVID-19 in critically ill patients in the Seattle region case series.N. Engl. J. Med.2020382212012202210.1056/NEJMoa2004500 32227758
     [Google Scholar]
  49. GoshayeshiL. Akbari RadM. BergquistR. AllahyariA. HashemzadehK. HoseiniB. Demographic and clinical characteristics of severe COVID-19 infections: A cross-sectional study from Mashhad University of Medical Sciences, Iran.BMC Infect. Dis.202121165610.1186/s12879‑021‑06363‑6 34233638
     [Google Scholar]
  50. KamalM.A. AlamiryK.R. ZakiM. Sex and age differences in telomere length and susceptibility to COVID-19.J. Biomed. Res. Environm. Sci.20201730331010.37871/jbres1159
     [Google Scholar]
  51. LiaoD. ZhouF. LuoL. Haematological characteristics and risk factors in the classification and prognosis evaluation of COVID-19: A retrospective cohort study.Lancet Haematol.202079e671e67810.1016/S2352‑3026(20)30217‑9 32659214
     [Google Scholar]
  52. NoorF.M. IslamM.M. Prevalence and associated risk factors of mortality among COVID-19 patients: A meta-analysis.J. Community Health20204561270128210.1007/s10900‑020‑00920‑x 32918645
     [Google Scholar]
  53. MartinezM.E. The calendar of epidemics: Seasonal cycles of infectious diseases.PLoS Pathog.20181411e100732710.1371/journal.ppat.1007327 30408114
     [Google Scholar]
  54. AltamimiA. AhmedA.E. Climate factors and incidence of Middle East respiratory syndrome coronavirus.J. Infect. Public Health202013570470810.1016/j.jiph.2019.11.011 31813836
     [Google Scholar]
  55. RahmanA. SathiN.J. Risk factors of the severity of COVID‐19: A meta‐analysis.Int. J. Clin. Pract.2021757e1391610.1111/ijcp.13916 33372407
     [Google Scholar]
  56. JangJ.G. HurJ. ChoiE.Y. HongK.S. LeeW. AhnJ.H. Prognostic factors for severe coronavirus disease 2019 in Daegu, Korea.J. Korean Med. Sci.20203523e20910.3346/jkms.2020.35.e209 32537954
     [Google Scholar]
  57. TianR. WuW. WangC. Clinical characteristics and survival analysis in critical and non-critical patients with COVID-19 in Wuhan, China: A single-center retrospective case control study.Sci. Rep.20201011752410.1038/s41598‑020‑74465‑3 33067568
     [Google Scholar]
  58. ZhangM.Q. WangX.H. ChenY.L. Clinical features of 2019 novel coronavirus pneumonia in the early stage from a fever clinic in Beijing.National Center for Biotech Inf2020430E01310.3760/cma.j.issn.1001‑0939.2020.0013 32061066
     [Google Scholar]
  59. YangX. YuY. XuJ. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study.Lancet Respir. Med.20208547548110.1016/S2213‑2600(20)30079‑5 32105632
     [Google Scholar]
  60. TalebiS. NematshahiM. TajabadiA. KhosrogerdiA. Comparison of clinical and epidemiological characteristics of deceased and recovered patients with COVID-19 in Sabzevar, Iran.J Mil Med2020226509516
     [Google Scholar]
  61. OnderG. RezzaG. BrusaferroS. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy.JAMA2020323181775177610.1001/jama.2020.4683 32203977
     [Google Scholar]
  62. AhmadiS. GargazM. The outlook for the cost of economic health in patients with COVID-19.Interdiscipl Stud Humanit2020123255410.22035/isih.2020.3939.4047
     [Google Scholar]
  63. TavakoliA. Novel coronavirus disease 2019 (COVID-19): An emergening infectious disease in the 21st century.Iran South Med J202022643245010.29252/ismj.22.6.432
     [Google Scholar]
  64. GoodwinA.T. ThompsonJ.S. HallI.P. Evaluation of outpatient treatment for non-hospitalised patients with COVID-19: The experience of a regional centre in the UK.PLoS One2023183e028191510.1371/journal.pone.0281915 36920896
     [Google Scholar]
  65. Price-HaywoodE.G. BurtonJ. FortD. SeoaneL. Hospitalization and mortality among black patients and white patients with Covid-19.N. Engl. J. Med.2020382262534254310.1056/NEJMsa2011686 32459916
     [Google Scholar]
  66. NguyenN.T. ChinnJ. KirbyK. HohmannS.F. AminA. Outcomes of COVID-19 adults managed in an outpatient versus hospital setting.PLoS One2022172e026381310.1371/journal.pone.0263813 35157718
     [Google Scholar]
  67. KeshavarzM. TavakoliA. ZanganehS. Clinical characteristics of outpatients and inpatients with COVID-19 in Bushehr: A report from the south of Iran.Future Virol.20211629910610.2217/fvl‑2020‑0231
     [Google Scholar]
  68. TenfordeM.W. Billig RoseE. LindsellC.J. Characteristics of adult outpatients and inpatients with COVID-19: 11 Academic Medical Centers, United States, March–May 2020.MMWR Morb. Mortal. Wkly. Rep.2020692684184610.15585/mmwr.mm6926e3 32614810
     [Google Scholar]
  69. BergquistS.H. PartinC. RobertsD.L. Non-hospitalized adults with COVID-19 differ noticeably from hospitalized adults in their demographic, clinical, and social characteristics.SN Compr. Clin. Med.2020291349135710.1007/s42399‑020‑00453‑3 32838186
     [Google Scholar]
  70. HuB. GuoH. ZhouP. ShiZ.L. Characteristics of SARS-CoV-2 and COVID-19.Nat. Rev. Microbiol.202119314115410.1038/s41579‑020‑00459‑7 33024307
     [Google Scholar]
  71. WangX FangX CaiZ Comorbid chronic diseases and acute organ injuries are strongly correlated with disease severity and mortality among COVID-19 patients: A systemic review and meta-analysis.Research202020202020/240296110.34133/2020/2402961 32377638
     [Google Scholar]
  72. CaiG. CuiX. ZhuX. ZhouJ. A hint on the COVID-19 Risk: Population disparities in gene expression of three receptors of SARS-CoVPreprints2020
     [Google Scholar]
  73. ClerkinK.J. FriedJ.A. RaikhelkarJ. COVID-19 and cardiovascular disease.Circulation2020141201648165510.1161/CIRCULATIONAHA.120.046941 32200663
     [Google Scholar]
  74. WangD. HuB. HuC. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China.JAMA2020323111061106910.1001/jama.2020.1585 32031570
     [Google Scholar]
  75. JaafarabadiM. BagheriM. ShariatM. The evaluation of clinical symptoms and underlying factors in infected patients with Covid-19.Tehran Univ. Med. J.20217810668677
     [Google Scholar]
  76. WangB. LiR. LuZ. HuangY. Does comorbidity increase the risk of patients with COVID-19: Evidence from meta-analysis.Aging20201276049605710.18632/aging.103000 32267833
     [Google Scholar]
  77. ChungR.Y.N. DongD. LiM.M. Socioeconomic gradient in health and the COVID-19 outbreak.BMJ2020369m132910.1136/bmj.m1329 32238351
     [Google Scholar]
  78. VitaleJ. MumoliN. ClericiP. Assessment of SARS-CoV-2 reinfection 1 year after primary infection in a population in Lombardy, Italy.JAMA Intern. Med.2021181101407140810.1001/jamainternmed.2021.2959 34048531
     [Google Scholar]
  79. AndewegS.P. de GierB. EgginkD. Protection of COVID-19 vaccination and previous infection against Omicron BA.1, BA.2 and Delta SARS-CoV-2 infections.Nat. Commun.2022131473810.1038/s41467‑022‑31838‑8 35961956
     [Google Scholar]
  80. StokesE.K. ZambranoL.D. AndersonK.N. Coronavirus disease 2019 case surveillance: United States, January 22–May 30, 2020.MMWR Morb. Mortal. Wkly. Rep.2020692475976510.15585/mmwr.mm6924e2 32555134
     [Google Scholar]
  81. LuoL. LiuD. LiaoX. Contact settings and risk for transmission in 3410 close contacts of patients with COVID-19 in Guangzhou, China.Ann. Intern. Med.20201731187988710.7326/M20‑2671 32790510
     [Google Scholar]
  82. DongE. DuH. GardnerL. An interactive web-based dashboard to track COVID-19 in real time.Lancet Infect. Dis.202020553353410.1016/S1473‑3099(20)30120‑1 32087114
     [Google Scholar]
  83. ZhuJ. JiP. PangJ. Clinical characteristics of 3062 COVID‐19 patients: A meta‐analysis.J. Med. Virol.202092101902191410.1002/jmv.25884 32293716
     [Google Scholar]
  84. Mousavi JazayeriS.A. Shahid fatemi field hospital services for patients with COVID -19 in Bandar Abbas, Iran.J Mil Med20202210991992
     [Google Scholar]
  85. DessieZ.G. ZewotirT. Mortality-related risk factors of COVID-19: A systematic review and meta-analysis of 42 studies and 423,117 patients.BMC Infect. Dis.202121185510.1186/s12879‑021‑06536‑3 34418980
     [Google Scholar]
  86. KönigS. PellissierV. HohensteinS. A comparative analysis of in-hospital mortality per disease groups in germany before and during the COVID-19 Pandemic From 2016 to 2020.JAMA Netw. Open202252e214864910.1001/jamanetworkopen.2021.48649 35166779
     [Google Scholar]
  87. LiX. LiT. WangH. Treatment and prognosis of COVID-19: Current scenario and prospects (Review).Exp. Ther. Med.2021211310.3892/etm.2015.2467 33235612
     [Google Scholar]
/content/journals/covid/10.2174/0126667975301350240627094313
Loading
Comparison of Characteristics and Clinical Symptoms of Inpatients and Outpatients with COVID-19
Coronaviruses 6, E050724231632 (2025); https://doi.org/10.2174/0126667975301350240627094313
/content/journals/covid/10.2174/0126667975301350240627094313
/content/journals/covid/10.2174/0126667975301350240627094313
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): COVID-19; inpatients; outpatients; PCR-RT; Prognosis; SARS-CoV

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test